medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2018, Number 1

<< Back

Rev Esp Med Quir 2018; 23 (1)

Melody® percutaneous pulmonary valve in Mexico. Initial experience in a patient with elevated surgical risk

Salgado-Sandoval A, Flores-Arizmendi A, Antúnez-Sánchez SP, Toro-Zapata C, Cortez-Leiva MA, Aceves-Chimal JL

Language: Spanish
References: 10
Page: 50-54
PDF size: 214.78 Kb.


ABSTRACT

The anatomical and functional disorders of the right ventricle outflow tract (RVOT) are common in the postoperative period of congenital heart disease. The implantation of allografts, bovine pulmonary vein and bioprostheses are standardized procedures in the pediatric population, requiring several surgical interventions during the life of the patient due to the deterioration of the grafts used, with increasing morbidity and mortality in each surgery. The Melody® percutaneous implantation valve (Medtronic, Minneapolis, MN, USA) is a less invasive alternative therapy for patients with very high surgical risk. We describe the first percutaneous implant of this valve in the pulmonary position in a patient undergoing two previous surgeries since childhood: Barbero Marcial and Rastelli with implantation of a 16 mm Contegra© graft with stenosis in both pulmonary branches that required stenting and redilatation. The implantation of the Melody® 20 mm valve was successful, without periprocedural complications, maintaining the patient in functional class I at six months of follow-up. Conclusion: The Melody® percutaneous valve can be a useful alternative for patients with congenital heart disease submitted to the previous implantation of biological grafts with very high surgical risk.


REFERENCES

  1. Gober V, Berdat P, Pavlovic M. Adverse mid-term outcome following RVOT reconstruction using the Contegra valved bovine jugular vein. Ann Thorac Surg. 2005;79:625-31.

  2. Sugita T, Ueda Y, Matsumoto M. Repeated procedure after radical surgery for tetralogy of Fallot. Ann Thorac Surg. 2000;70(5):1507-10.

  3. Peng LF, McElhinney DB, Nugent AW, Powell AJ, Marshal AC, Bacha EA, et al. Endovascular stenting of obstructed right ventricle-to-pulmonary artery conduits: a 15-year experience. Circulation. 2006;113(22):2598-605.

  4. Powell AJ, Lock JE, Keane JF, Perry SB. Prolongation of RV-PA conduit life span by percutaneous stent implantation: intermediate- term results. Circulation. 1995;92(11):3282-8.

  5. Bonhoeffer P, Boudjemline Y, Saliba Z. Percutaneous replacement of pulmonary valve in right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet. 2000;356:1403-05.

  6. McElhinney DB, Hellebrand WE, Zahn EM. Short- and medium- term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US Melody valve trail. Circulation. 2010;122:507-16.

  7. Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the U.S. Clinical trial. J Am Coll Cardiol. 2009;54(18):1722-9.

  8. Lurz P, Coats L, Khambadkone S. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. Circulation. 2008;117:1964-72.

  9. Eicken A, Ewert P, Hager A, Peters B, Fratz S, Kuehne T, et al. Percutaneous pulmonary valve implantation: two-center experience with more than 100 patients. Eur Heart J. 2011;32:1260-5.

  10. Guccione P, Gagliardi MG, Calcagni G, Alvarez A, Pongiglione G. Percutaneous implantation of pulmonary valves for treatment of right ventricular outflow tract dysfunction: a single-centre experience. J Pead. 2009;19:S116-9.




2020     |     www.medigraphic.com